Bonderman Diana, Turecek Peter L, Jakowitsch Johannes, Weltermann Ansgar, Adlbrecht Christopher, Schneider Barbara, Kneussl Meinhard, Rubin Lewis J, Kyrle Paul A, Klepetko Walter, Maurer Gerald, Lang Irene M
Department of Internal Medicine II, Division of Cardiology, University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.
Thromb Haemost. 2003 Sep;90(3):372-6. doi: 10.1160/TH03-02-0067.
Chronic thromboembolic pulmonary hypertension (CTEPH) is an enigmatic disorder lacking signs, symptoms and classical risk factors for venous thromboembolism. The objective of the prospective case controlled study, carried out at the Pulmonary Hypertension Unit, University Hospital Vienna, Austria, was to investigate whether plasma FVIII is elevated in CTEPH patients. The study examined 122 consecutive patients diagnosed with CTEPH. Plasma FVIII was measured and compared with plasma FVIII of healthy controls (n = 82) and of patients with nonthromboembolic pulmonary arterial hypertension (PAH, n = 88). Results show that CTEPH patients had higher FVIII levels than controls (233 +/- 83IU/dl versus 123 +/- 40IU/dl, p < 0.0001) and PAH patients (158 +/- 61IU/dl, p < 0.0001). Plasma FVIII one year after surgery (212 +/- 94IU/dl) was statistically unchanged compared with preoperative values (FVIII: 226 +/- 88IU/dl, n = 25). FVIII > 230IU/dl was more prevalent in CTEPH patients (41%) than in controls (5%, p < 0.0001) and PAH patients (22%, p = 0.022). We can conclude that elevated plasma FVIII is the first prothrombotic factor identified in a large proportion of CTEPH patients.
慢性血栓栓塞性肺动脉高压（CTEPH）是一种难以捉摸的疾病，缺乏静脉血栓栓塞的体征、症状和经典危险因素。在奥地利维也纳大学医院肺动脉高压科进行的这项前瞻性病例对照研究的目的是调查CTEPH患者的血浆FVIII是否升高。该研究检查了122例连续诊断为CTEPH的患者。测量了血浆FVIII，并与健康对照组（n = 82）和非血栓栓塞性肺动脉高压（PAH，n = 88）患者的血浆FVIII进行了比较。结果显示，CTEPH患者的FVIII水平高于对照组（233±83IU/dl对123±40IU/dl，p < 0.0001）和PAH患者（158±61IU/dl，p < 0.0001）。术后一年的血浆FVIII（212±94IU/dl）与术前值（FVIII：226±88IU/dl，n = 25）相比，在统计学上没有变化。FVIII>230IU/dl在CTEPH患者中（41%）比在对照组（5%，p < 0.0001）和PAH患者中（22%，p = 0.022）更为普遍。我们可以得出结论，血浆FVIII升高是在大部分CTEPH患者中发现的首个促血栓形成因素。
